title: Beneficial effects of edaravone on the expression of serum matrix metalloproteinase-9 after cerebral hemorrhage.
abstract: OBJECTIVE
  To explore the effects of edaravone on the expression of matrix metalloproteinase-9 (MMP-9) posterior to cerebral hemorrhage, and to analyze the relationship between this expression and neurological deficit.
  
  
  METHODS
  A total of 160 basal ganglia hemorrhage patients enrolled in Dongfeng Hospital, Hubei University of Medicine, Shiyan, China between April 2009 and July 2011 were included and divided into a treatment group and a control group (n=80). All patients were treated with minimally invasive hematoma evacuation, and the treatment group was administered with edaravone simultaneously. Serum MMP-9 levels were measured by double-antibody sandwich enzyme-linked immunosorbent assay. The National Institutes of Health Stroke Scale (NIHSS) and Glasgow Coma Scale scores of the 2 groups were determined before and after treatment.
  
  
  RESULTS
  The overall effective rates of the treatment (86.3%) and control (75.0%) groups differed significantly (p<0.05). The serum MMP-9 levels of the 2 groups that were similar (p>0.05) before treatment significantly decreased (p<0.05) after treatment, and those of the 2 groups also differed significantly (p<0.05). The NIHSS scores of the 2 groups that were similar (p>0.05) before treatment also significantly decreased (p<0.05) after treatment, and those of the 2 groups differed significantly (p<0.05). Pearson`s correlation analysis revealed that the level of serum MMP-9 was significantly correlated with the NIHSS score before treatment (R=0.491).
  
  
  CONCLUSIONS
  Combined minimally invasive hematoma evacuation and edaravone effectively treated cerebral hemorrhage by directly lowering the level of serum MMP-9.
authors.affiliation: Department of Neurology, Zhen`An County Hospital, Zhen`an, P. R. China.
authors.forename: Fahui
authors.initials: F
authors.lastname: Zhao
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002543:Cerebral Hemorrhage / Q000097:blood* / Q000188:drug therapy*; D000077553:Edaravone; D005260:Female; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D015600:Glasgow Coma Scale; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D012720:Severity of Illness Index; D013223:Statistics as Topic
chemical_list: D016166:Free Radical Scavengers; D020780:Matrix Metalloproteinase 9; D000077553:Edaravone; D000983:Antipyrine